Company Filing History:
Years Active: 2009
Title: The Innovative Contributions of William Rideout, III
Introduction
William Rideout, III is a notable inventor based in Cambridge, MA. He has made significant contributions to the field of cancer research through his innovative work in developing chimeric cancer models. His research focuses on creating nonhuman mammals that serve as inducible spontaneous cancer models, which can greatly enhance our understanding of cancer mechanisms.
Latest Patents
William Rideout, III holds a patent for his invention titled "Chimeric cancer models." This patent describes chimeric nonhuman mammals that are useful as inducible spontaneous cancer models. The process involves introducing genetically modified embryonic stem (ES) cells into an early-stage embryo, which is then implanted into a surrogate mother. The ES cells contain a recombinant oncogene and may also include a genetic mutation that deletes or inactivates a tumor suppressor gene. By introducing various combinations of genetic mutations into the ES cells, models of different types of cancer can be produced.
Career Highlights
William Rideout, III is currently associated with Aveo Pharmaceuticals, Inc., where he continues to advance his research in cancer models. His work is pivotal in developing new strategies for cancer treatment and understanding the complexities of tumor biology.
Collaborations
He collaborates with esteemed colleagues such as Joerg Heyer and Murray Robinson, who contribute to the innovative research environment at Aveo Pharmaceuticals, Inc.
Conclusion
William Rideout, III's contributions to cancer research through his patented chimeric cancer models represent a significant advancement in the field. His work not only enhances our understanding of cancer but also paves the way for future therapeutic developments.